checkAd

    1000% chance =der reichmacher= - 500 Beiträge pro Seite

    eröffnet am 18.08.05 00:55:19 von
    neuester Beitrag 18.08.05 10:58:06 von
    Beiträge: 3
    ID: 1.000.845
    Aufrufe heute: 0
    Gesamt: 706
    Aktive User: 0


     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 18.08.05 00:55:19
      Beitrag Nr. 1 ()
      http://biz.yahoo.com/e/050812/nzym8-k.html

      "In spite of our recent results, Synthetech`s pipeline of clinical projects remains robust, with about a dozen active projects in mid- to late-stage clinical trials for which we are supplying key intermediates and many other projects at earlier stages of the drug development cycle. We expect to be named as an approved supplier of intermediates in three New Drug Applications to be filed by our customers during fiscal 2006 following completion of Phase 3 clinical trials currently in progress. Synthetech has supported each of these projects for years as they have progressed through the drug development cycle. Although we face a challenging environment in the near-term, we believe that Synthetech`s pipeline of projects has the potential to generate longer-term revenue significantly above amounts in recent fiscal years."

      The three drugs under development mentioned above relate to the treatment of diabetes and cancer and to veterinary applications, respectively. Synthetech has received another order relating to the diabetes drug project for delivery in November 2005. The cancer drug is targeted at multiple indications, with two indications in Phase 3 clinical trials and others in Phase 2 trials. The cancer drug likely would be subject to fast-track approval by the U.S. Food and Drug Administration, which would take at least six months following the New Drug Application filing.

      Management believes that, if the drugs receive regulatory approval and market acceptance, the diabetes drug could result eventually in annual revenue to Synthetech in the range of $3 to 10 million, and that all three drugs could result eventually in annual revenue to Synthetech of approximately $15 million. However, none of these drugs may be approved, and even though Synthetech expects to be named as an approved supplier in the New Drug Applications, there is no assurance with respect to the timing, volume, frequency or repetition of orders.




      :lick:

      mfg
      Avatar
      schrieb am 18.08.05 01:00:31
      Beitrag Nr. 2 ()
      Kannst mal die übersetzung reinstellen und ne Prognose machen!?:)
      Avatar
      schrieb am 18.08.05 10:58:06
      Beitrag Nr. 3 ()
      knacken wir diese woche die 1$??????:lick:

      mein kursziel längerfristig über 5$

      wenn dann noch eine big news kommt wer weiß
      10$?


      Synthetech wird der hammer nach der letzten news!!!


      die aktie steht vor einer neubewertung!


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      1000% chance =der reichmacher=